- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
CECP's CEO Investor Forum and Biopharma Sustainability Roundtable Release Report on Integrating Sustainability and Long-Term Planning for the Biopharma Sector
Research shows ESG performance is strongly predictive of long-term value creation and financial performance, when a sector-specific approach is maintained.
As the world begins to emerge from under the weight of multiple crises, investors are seeking more effective and efficient ESG (environment, social, and governance) communications directly from companies, which include a longer-term strategy and vision. Answering that call, Chief Executives for Corporate Purpose’s (CECP) CEO Investor Forum, an advisor that empowers CEOs on their journey to refocus investor expectations toward the long term, and the Biopharma Sustainability Roundtable (BSRT), a sector-specific collaboration platform that works with senior biotech and pharma executives to help drive their sustainability agendas forward, released a joint report on Integrating Sustainability and Long-Term Planning for the Biopharma Sector.
The new report, together with a companion practitioner’s guide, provide sector-specific tools for biopharma CEOs and their teams as they prepare sustainable Long-Term Plans to share with investors. Combining CECP’s Long-Term Plan framework and BSRT’s Biopharma Investor ESG Communications Guidance will help tailor content and perspective for the biopharma sector.
For more information and the full report, click here.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
